Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
37 hedge funds and large institutions have $51.5M invested in Sorrento Therapeutics, Inc. in 2014 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 9 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 6
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
78% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 9
23% more funds holding
Funds holding: 30 → 37 (+7)
8% less capital invested
Capital invested by funds: $55.9M → $51.5M (-$4.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aisling Capital
New York
|
+$8.62M |
| 2 |
TC
Talkot Capital
Sausalito,
California
|
+$5.25M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$2.26M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.51M |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
+$1.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
-$566K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$396K |
| 3 |
LP
LMR Partners
London,
United Kingdom
|
-$387K |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$385K |
| 5 |
Jane Street
New York
|
-$357K |
SRNE Hedge Fund Activity: Q2 2014 in Review
37 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q2 2014, worth a combined $51.5M — down 7.7% from $55.9M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new SRNE positions and 9 closed out — a net gain of 7 holders — while 14 added to existing stakes and 6 trimmed.
The largest buyer was Aisling Capital, adding an estimated $8.62M. The largest seller was Neuberger Berman Group, exiting entirely with an estimated $566K sold.
- 37 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q2 2014, up from 30 in Q1 2014.
- Funds reported $51.5M of Sorrento Therapeutics, Inc. stock for Q2 2014, down 7.7% quarter-over-quarter.
- 16 funds opened new Sorrento Therapeutics, Inc. positions in Q2 2014 and 9 closed out, a net change of +7 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q2 2014 was Aisling Capital, an estimated $8.62M added.
- The largest Sorrento Therapeutics, Inc. seller in Q2 2014 was Neuberger Berman Group, an estimated $566K sold.
Based on aggregated 13F filings for Q2 2014.